Role of Diabetes Mellitus on Adverse Drug Reaction to Anti-tuberculosis Drugs

Main Article Content

Daud M. Ishaq Aweis
Syed Azhar Syed Suleiman

Abstract

Introduction: Tuberculosis (TB) is one of the leading cause of death among infectious diseases. The dual burden of TB and diabetes mellitus (DM) is a major economic and health concern. Anti-TB therapy may predispose patients to develop adverse drug reaction (ADR). The effect of DM on anti-TB ADR requires more studies.

Methods: We performed a cross-sectional study and followed patients for at least two  years. Patients were selected from three Malaysian teaching hospitals. TB patients, and diabetic patients with TB were divided into two groups of 200 subjects each. Data were obtained from patients’ medical files at the beginning and end of the study  period. Prevalence of serious adverse drug reaction (ADR) requiring dose adjustment was assessed.

Results: ADR in our subjects was documented in the medical records and confirmed by a system known as Challenge. The prevalence rates of ADR amongst DM-TB and TB only patients were 16.5% and 14.8%, respectively, but the difference was not significant (Fisher E.T: P > 0.05). ADR was more frequent with streptomycin treatment, partially because of its painful administration. Isoniazid treatment showed the least frequency of ADR.

Conclusion: Although the frequency of ADR was high among DM-TB patients, it was not significantly different to that among TB only patients.

Keywords:
Anti-tuberculosis, diabetes mellitus, drug, ADR.

Article Details

How to Cite
Aweis, D. M. I., & Suleiman, S. A. S. (2020). Role of Diabetes Mellitus on Adverse Drug Reaction to Anti-tuberculosis Drugs. Journal of Advances in Medical and Pharmaceutical Sciences, 22(7), 34-39. https://doi.org/10.9734/jamps/2020/v22i730183
Section
Original Research Article

References

Lien LT, Hang NTL, Kobayashi N, Yanai H, Toyota E, et al. Prevalence and Risk Factors for Tuberculosis Infection among Hospital Workers in Hanoi, Viet Nam. PLoS ONE. 2009;4(8):6798. DOI:10.1371/journal.pone.0006798

Oxlade O, Murray M. Tuberculosis and Poverty: Why Are the Poor at Greater Risk in India? PLoS ONE. 2012;7(11):47533. DOI:10.1371/ journal.pone.0047533

WHO, Cummunicable Disease: Tuberculosis Fact Sheet; 2016. Available:http://www.searo.who.int/en/Section10/Section2097/ Section2106 10682.htm.

Boucot KR. Diabetes mellitus and pulmonary tuberculosis. Journal of Chronic Diseases. 1957;6(3):256-279.

Masoodi SR, Wani AI, Misgar RA, Gupta VK, Bashir MI, Zargar AH. Pattern of infections in patients with diabetes mellitus--Data from a tertiary care medical centre in Indian sub-continent. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2007;1(2):91-95.

Syed Azhar Syed Suleiman, Daud M. Ishaq Aweis, Ali Jimale Mohamed, Abdul RazakMuttalif, and Mohamed A. A. Moussa. Role of Diabetes in the Prognosis and Therapeutic Outcome of Tuberculosis. International Journal of Endocrinology. Article ID 645362. 2012;6. DOI:10.1155/2012/645362.

AN Siddiqui et al. Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study. BioMed Research International. Article ID 7273935. 2016;11. Available:http://dx.doi.org/10.1155/2016/7273935

Duangrithi D. Impact of diabetes mellitus on clinical parameters and Treatment outcomes of newly diagnosed pulmonary tuberculosis patients in Thailand. Int J Clin Pract. 2013;67(11):1199-209. DOI:10.1111/ijcp.12215.

BE Gu¨lbay et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respiratory Medicine. 2006;100:1834–1842.

XQ Han et al. Prevalence and Risk Factors Associated with Adverse Drug Reactions among Previously Treated Tuberculosis Patients in China. Biomed Environ Sci. 2017;30(2):139-142.

A Farazi et al. Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients. Tuberculosis Research and Treatment. Article ID 412893; 2014.